Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells

BackgroundHistone deacetylase (HDAC) inhibitors are widely used in clinical investigation as novel drug targets. For example, panobinostat and vorinostat have been used to treat patients with melanoma. However, HDAC inhibitors are small-molecule compounds without a specific target, and their mechanism of action is unclear. Therefore, it is necessary to investigate which HDACs are required for the proliferation and metastasis of melanoma cells.MethodsWe used overexpression and knocking down lentivirus to clarify the influence of HDAC5 and HDAC6 in melanoma development. Also, we introduced stable HDAC5 or HDAC6 knockdown cells into null mice and found that the knockdown cells were unable to form solid tumors. Finally, we tested HDAC5 and HDAC6 expression and sub-location in clinical melanoma tissues and tumor adjacent tissues.ResultsIn this study, and found that HDAC5 and HDAC6 were highly expressed in melanoma cells but exhibited low expression levels in normal skin cells. Furthermore, we knocked down HDAC5 or HDAC6 in A375 cells and demonstrated that both HDAC5 and HDAC6 contributed to the proliferation and metastasis of melanoma cells.ConclusionsThis study demonstrated both HDAC5 and HDAC6 were required for melanoma cell proliferation and metastasis through different signaling pathways.

[1]  A. Bershadsky,et al.  Regulation of microtubule dynamics by inhibition of the tubulin deacetylase HDAC6 , 2009, Journal of Cell Science.

[2]  W. Hall,et al.  Brain metastases: Histology, multiplicity, surgery, and survival , 1996 .

[3]  E. Olson,et al.  Histone Deacetylase 5 Acquires Calcium/Calmodulin-Dependent Kinase II Responsiveness by Oligomerization with Histone Deacetylase 4 , 2008, Molecular and Cellular Biology.

[4]  P. Hersey,et al.  Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3 , 2013, Cell Death and Disease.

[5]  P. Xing,et al.  Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas , 2012, Cancer Chemotherapy and Pharmacology.

[6]  M. Gleave,et al.  NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. , 2006, Cancer cell.

[7]  Francis J Giles,et al.  Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. , 2008, Cancer letters.

[8]  Yoshiharu Kawaguchi,et al.  HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions , 2007, Journal of Cell Science.

[9]  P. Matthias,et al.  The deacetylase HDAC6 is a novel critical component of stress granules involved in the stress response. , 2007, Genes & development.

[10]  Michael B Atkins,et al.  Management of cutaneous melanoma. , 2004, The New England journal of medicine.

[11]  J. Verweij,et al.  A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors , 2012, Clinical Cancer Research.

[12]  Joo-Yong Lee,et al.  Histone Deacetylase 6 Regulates Growth Factor-Induced Actin Remodeling and Endocytosis , 2007, Molecular and Cellular Biology.

[13]  Kristen M. Naegle,et al.  Injury-Induced HDAC5 Nuclear Export Is Essential for Axon Regeneration , 2013, Cell.

[14]  E. Olson,et al.  Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S. Steinberg,et al.  Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  E. Barberá‐Guillem,et al.  Management of cutaneous melanoma. , 2004, The New England journal of medicine.

[17]  N. Bertos,et al.  Role of the Tetradecapeptide Repeat Domain of Human Histone Deacetylase 6 in Cytoplasmic Retention* , 2004, Journal of Biological Chemistry.

[18]  S. Tucker,et al.  Histone Deacetylase Inhibitors Radiosensitize Human Melanoma Cells by Suppressing DNA Repair Activity , 2005, Clinical Cancer Research.

[19]  J. Golfinos,et al.  A Comparison of Survival Rates for Treatment of Melanoma Metastatic to the Brain , 2004, Cancer investigation.

[20]  Y. Qiao,et al.  HDAC6 siRNA inhibits proliferation and induces apoptosis of HeLa cells and its related molecular mechanism. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[21]  R. James,et al.  Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. , 1997, Cancer research.

[22]  J. Garin,et al.  Identification of Components of the Murine Histone Deacetylase 6 Complex: Link between Acetylation and Ubiquitination Signaling Pathways , 2001, Molecular and Cellular Biology.

[23]  C. Brancolini,et al.  The Control Operated by the Cell Cycle Machinery on MEF2 Stability Contributes to the Downregulation of CDKN1A and Entry into S Phase , 2015, Molecular and Cellular Biology.

[24]  A. V. van Kuilenburg,et al.  Histone deacetylases (HDACs): characterization of the classical HDAC family. , 2003, The Biochemical journal.

[25]  P. Marks,et al.  Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Xinwen Chen,et al.  The histone deacetylase inhibitor sodium butyrate inhibits baculovirus-mediated transgene expression in Sf9 cells. , 2007, Journal of biotechnology.

[27]  A. Verdel,et al.  mHDA1/HDAC5 Histone Deacetylase Interacts with and Represses MEF2A Transcriptional Activity* , 2000, The Journal of Biological Chemistry.

[28]  Dan Garza,et al.  HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS , 2007, Nature.

[29]  F. Child,et al.  Management of cutaneous T-cell lymphoma. , 2012, Clinical medicine (London).

[30]  Xiao-Fan Wang,et al.  The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. , 2008, Cancer research.

[31]  Chunlei Zhang,et al.  Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). , 2007, Blood.

[32]  Hansjoerg Keller,et al.  Class I and IIa Histone Deacetylases Have Opposite Effects on Sclerostin Gene Regulation , 2014, Journal of Biological Chemistry.

[33]  Lucia Altucci,et al.  Trials with ‘epigenetic’ drugs: An update , 2012, Molecular oncology.

[34]  B. Kemp,et al.  AMP-Activated Protein Kinase Regulates GLUT4 Transcription by Phosphorylating Histone Deacetylase 5 , 2008, Diabetes.

[35]  D. Fairlie,et al.  Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. , 2000, Molecular biology of the cell.

[36]  R. Liu,et al.  Helicobacter pylori enhances cyclooxygenase 2 expression via p38MAPK/ATF-2 signaling pathway in MKN45 cells. , 2009, Cancer letters.

[37]  T. Abe,et al.  The histone deacetylase inhibitor butyrate inhibits melanoma cell invasion of Matrigel. , 2007, Anticancer research.

[38]  Y. Liu,et al.  The MSHA Strain of Pseudomonas Aeruginosa Activated TLR Pathway and Enhanced HIV-1 DNA Vaccine Immunoreactivity , 2012, PloS one.

[39]  A. Biankin,et al.  Histone deacetylase 5 blocks neuroblastoma cell differentiation by interacting with N-Myc , 2014, Oncogene.

[40]  J. Vose,et al.  A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL) , 2012 .

[41]  P. Marks,et al.  Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.

[42]  W. Jin,et al.  Inhibition of EGFR pathway signaling and the metastatic potential of breast cancer cells by PA-MSHA mediated by type 1 fimbriae via a mannose-dependent manner , 2010, Oncogene.

[43]  K. Haigis,et al.  HDAC6 and SIRT2 Regulate the Acetylation State and Oncogenic Activity of Mutant K-RAS , 2013, Molecular Cancer Research.

[44]  Tongshan Wang,et al.  Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials. , 2013, Future oncology.

[45]  Minoru Yoshida,et al.  Bone Morphogenetic Protein-2 Stimulates Runx2 Acetylation* , 2006, Journal of Biological Chemistry.

[46]  M. Caligiuri,et al.  A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. , 2012, Blood.

[47]  Wei Chen,et al.  Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest , 2014, Tumor Biology.

[48]  J. Becker,et al.  Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  P. Hersey,et al.  The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance. , 2013, Carcinogenesis.

[50]  A. Fischer,et al.  Loss of HDAC5 impairs memory function: implications for Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[51]  Y. Xiong,et al.  Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization. , 2013, Molecular cell.

[52]  Chun‐Hsiang Lai,et al.  Microtubule acetylation amplifies p38 kinase signaling and anti-inflammatory IL-10 production , 2014, Nature Communications.

[53]  R. Evans,et al.  Class IIa Histone Deacetylases Are Hormone-Activated Regulators of FOXO and Mammalian Glucose Homeostasis , 2011, Cell.

[54]  Minoru Yoshida,et al.  HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. , 2005, Molecular cell.